

Forelesere på årets hovedprogram



Steinar Amdal
Professor, MD, PhD
Oslo universitetssykehus

Fredag 14:20

Clinical new drug development, Phase I and Phase II trials, immunotherapy, vaccines (dendritic cell vaccines, peptide vaccines), cytotoxic drugs. Founder of Phase I/Phase II Research Unit in 1995, which now is one of the largest of its kind in Scandinavia, treating more than 100 patients in clinical trials yearly.



Anthony Back
Co-Director, Medical oncologist
Cambia Palliative Care Center of Excellence

Fredag 09:45

Dr. Back is a Co-Director of the Cambia Palliative Care Center of Excellence with Dr. Randy Curtis. His research on patient-physician communication has been funded by the National Cancer Institute, Robert Wood Johnson Foundation, Gordon and Betty Moore Foundation, Arnold P Gold Foundation and many others.



Rune Blomhoff
Professor
Universitetet i Oslo

Torsdag 09:45



Rodrigo Dienstmann
Medical oncologist, data scientist
Vall d'Hebron Institute of Oncology

Torsdag 10:15

Medical oncologist with expertise in drug-biomarker co-development in early clinical trials. He is Principal Investigator of the Oncology Data Science Group, integrating clinical and translational research with genomics and immunophenotyping of tumors for precision cancer therapy.



Hans Petter Eikesdal
Consultant breast cancer oncologist
Haukeland universitetssjukehus

Fredag 12:15

Consultant oncologist 50% and senior researcher 50% at Dept. of Oncology, Haukeland Hospital and Mohn Cancer Research Laboratory, Dept. of Clinical Science, UIB. National principal investigator for the PETREMAC phase 2 clinical trial, where personalized cancer therapy is given based on molecular markers.



Sissi Espetvedt
MD/ PhD/ Spesialist i onkologi
Helsedirektoratet

Fredag 11:40

Onkolog, Kreftstrategien, Helsedirektoratet



Anne Forus
Seniorrådgiver
Helsedirektoratet

Fredag 11:40

Jeg er molekylærbiolog med doktorgrad innen kreftforskning. Jeg har arbeidet i Helsedirektoratet siden 2003; mest med biomedisin og bioteknologi (fosterdiagnostikk, assistert befruktning, genetik) og litt med kreftområdet. I prosjekt Persontilpasset medisin arbeider jeg med internasjonale saker, normering, genetik og kreft.



Kari Grønås

Fredag 12:50

Lang fartstid i norske legemiddelskaper, Nycomed Imaging, PhotoCure og Algeta med utvikling av nye medikamenter. Arbeider i dag som konsulent, og sitter i 2 styre (Lytx Biopharma og BergenBio). Ble selv rammet av kreft og er her i dag som pasient.



Marcel van Herk
Chair in radiotherapy physics
University of Manchester

Torsdag 11:50

Worked many years in NKI in Amsterdam, since 2.5 years in Manchester. I study everything to do with the precision of radiotherapy, ranging from observer variation, image guidance and margins through to data mining to learn about tumour spread and normal tissue toxicity. Many systems I developed are clinical.



Cecilie E Kiserud
Overlege, spesialist i onkologi, PhD
Oslo universitetssykehus

Fredag 10:30

Leder av Nasjonal kompetansetjeneste for seneffekter etter kreft, avdeling for kreftbehandling. Arbeider med forskning og formidling om seneffekter etter kreftbehandling.



Alessandro Laviano
MD
Sapienza University of Rome

Torsdag 09:15

Member of the Nutrition Team at University Hospital in Rome. Research Interest: cancer anorexia-cachexia. Editor in chief, Nutrition. Director, ESPEN LLL Educational Programme.



Gunhild M. Mælandsmo
Prof, PhD
Oslo universitetssykehus

Fredag 12:00

Research group leader at Institute for Cancer Research focusing on Metastasis Biology and Experimental Therapeutics. PI for the MetAction project; Actionable Targets in Cancer Metastasis - including the first Norwegian clinical trial in precision oncology where treatment decisions are based on broad NGS sequencing.



Fredrik Schjesvold
Head of Oslo Myeloma Center
Oslo universitetssykehus

Fredag 13:40

Started and currently leads Oslo Myeloma Center. Member of the International Myeloma Working Group. National coordinator of 15 clinical studies in myeloma, site coordinator of 4 studies, and Nordic study lead in one study.



Frode Skanke
Medisinsk faglig ansvarlig
LHL-klinikkene Røros

Fredag 10:55

Mangeårig spesialist i allmennmedisin og har arbeidet i flere år ved Kreftklinikken St. Olavs hospital. Videreutdannet i palliativ medisin. Fra 2010 har han vært ansatt ved LHL-klinikkene Røros, en institusjon som gir rehabiliteringstilbud til kreftpasienter.



Torgrim Tandstad
Overlege, PhD
Kreftklinikken St. Olavs hospital, Trondheim

Torsdag 12:10

Overlege og forsker på urogenital kreft ved St. Olavs hospital i Trondheim.



Morten Mau-Sørensen
Head of Unit, MD, PhD
Dept of Onc., Rigshospitalet, Copenhagen

Fredag 14:00

Part of my work is as Chair of the Accreditation and Designation Board of the Organisation of European Cancer Institutes (OEI). I shall be speaking on the need for Quality Standards in Cancer at an Institutional level not simply a pathway level, and why external validation and accreditation is an important improvement mechanism.



Simon Oberst
Director of Clinical Development
CRUK Cambridge Centre and OEI

Torsdag 11:15

Part of my work is as Chair of the Accreditation and Designation Board of the Organisation of European Cancer Institutes (OEI). I shall be speaking on the need for Quality Standards in Cancer at an Institutional level not simply a pathway level, and why external validation and accreditation is an important improvement mechanism.



Per Ottar Seglen
Professor
Centre for Molecular Medicine Norway

Fredag 08:30

Forsker på BULK-AUTOFAGI, en autofag-lysosomal prosess for generell (non-selektiv) nedbrytning av celleprotein. Prosessen bremser cellulær massevekst og celledeling, og kan (hvis uhindret) forårsake celledød. Bulk-autofagi er som regel sterkt redusert i kreftceller, som derved bedrer sin proteinbalanse, overlevelses-evne og vekst.



Sigbjørn Smeland
Klinikkleder og professor
Oslo universitetssykehus og UiO

Torsdag 11:35

Klinikkleder for Kreftklinikken. Leder av driftsstyret for kreft i OUS. Spesialist i onkologi. Professor ved institutt for klinisk medisin.



Giske Ursin
Direktør
Kreftregisteret

Fredag 12:30

Dr. Giske Ursin is Director of the Cancer Registry of Norway. She is Professor II at the Institute of Basic Medical Sciences at the University of Oslo, and Professor Emerita at the Department of Preventive Medicine, Keck School of Medicine at the University of Southern California.